Subcutaneous RYBREVANT®▼ (amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer ...

South Africa’s latest Cabinet-approved Integrated Resource Plan (IRP 2025) includes several policy adjustments that deviate ...